192 related articles for article (PubMed ID: 29110408)
1. Design, Synthesis, Biological Evaluation, and X-ray Studies of HIV-1 Protease Inhibitors with Modified P2' Ligands of Darunavir.
Ghosh AK; Fyvie WS; Brindisi M; Steffey M; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
ChemMedChem; 2017 Dec; 12(23):1942-1952. PubMed ID: 29110408
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of darunavir-derived HIV-1 protease inhibitors incorporating P2' amide-derivatives: Synthesis, biological evaluation and structural studies.
Ghosh AK; Shahabi D; Kipfmiller M; Ghosh AK; Johnson M; Wang YF; Agniswamy J; Amano M; Weber IT; Mitsuya H
Bioorg Med Chem Lett; 2023 Mar; 83():129168. PubMed ID: 36738797
[TBL] [Abstract][Full Text] [Related]
3. Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure-Activity Studies, Biological and X-ray Structural Analysis.
Ghosh AK; R Nyalapatla P; Kovela S; Rao KV; Brindisi M; Osswald HL; Amano M; Aoki M; Agniswamy J; Wang YF; Weber IT; Mitsuya H
J Med Chem; 2018 May; 61(10):4561-4577. PubMed ID: 29763303
[TBL] [Abstract][Full Text] [Related]
4. Piperidine scaffold as the novel P2-ligands in cyclopropyl-containing HIV-1 protease inhibitors: Structure-based design, synthesis, biological evaluation and docking study.
Zhou H; Zhu M; Ma L; Zhou J; Dong B; Zhang G; Cen S; Wang Y; Wang J
PLoS One; 2020; 15(7):e0235483. PubMed ID: 32697773
[TBL] [Abstract][Full Text] [Related]
5. Potent HIV-1 Protease Inhibitors Containing Carboxylic and Boronic Acids: Effect on Enzyme Inhibition and Antiviral Activity and Protein-Ligand X-ray Structural Studies.
Ghosh AK; Xia Z; Kovela S; Robinson WL; Johnson ME; Kneller DW; Wang YF; Aoki M; Takamatsu Y; Weber IT; Mitsuya H
ChemMedChem; 2019 Nov; 14(21):1863-1872. PubMed ID: 31549492
[TBL] [Abstract][Full Text] [Related]
6. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands.
Ghosh AK; Sean Fyvie W; Brindisi M; Steffey M; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
Bioorg Med Chem Lett; 2017 Nov; 27(21):4925-4931. PubMed ID: 28958624
[TBL] [Abstract][Full Text] [Related]
8. Potent cyclic urea HIV protease inhibitors with 3-aminoindazole P2/P2' groups.
Rodgers JD; Johnson BL; Wang H; Erickson-Viitanen S; Klabe RM; Bacheler L; Cordova BC; Chang CH
Bioorg Med Chem Lett; 1998 Apr; 8(7):715-20. PubMed ID: 9871528
[TBL] [Abstract][Full Text] [Related]
9. Design of gem-difluoro-bis-tetrahydrofuran as P2 ligand for HIV-1 protease inhibitors to improve brain penetration: synthesis, X-ray studies, and biological evaluation.
Ghosh AK; Yashchuk S; Mizuno A; Chakraborty N; Agniswamy J; Wang YF; Aoki M; Gomez PM; Amano M; Weber IT; Mitsuya H
ChemMedChem; 2015 Jan; 10(1):107-15. PubMed ID: 25336073
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.
Ghosh AK; Kulkarni S; Anderson DD; Hong L; Baldridge A; Wang YF; Chumanevich AA; Kovalevsky AY; Tojo Y; Amano M; Koh Y; Tang J; Weber IT; Mitsuya H
J Med Chem; 2009 Dec; 52(23):7689-705. PubMed ID: 19746963
[TBL] [Abstract][Full Text] [Related]
11. Structure-Based Design of Highly Potent HIV-1 Protease Inhibitors Containing New Tricyclic Ring P2-Ligands: Design, Synthesis, Biological, and X-ray Structural Studies.
Ghosh AK; Kovela S; Osswald HL; Amano M; Aoki M; Agniswamy J; Wang YF; Weber IT; Mitsuya H
J Med Chem; 2020 May; 63(9):4867-4879. PubMed ID: 32348139
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of novel HIV-1 protease inhibitors using tertiary amine as P2-ligands.
Yang ZH; Bai XG; Zhou L; Wang JX; Liu HT; Wang YC
Bioorg Med Chem Lett; 2015 May; 25(9):1880-3. PubMed ID: 25838144
[TBL] [Abstract][Full Text] [Related]
13. Design and Synthesis of Potent HIV-1 Protease Inhibitors Containing Bicyclic Oxazolidinone Scaffold as the P2 Ligands: Structure-Activity Studies and Biological and X-ray Structural Studies.
Ghosh AK; Williams JN; Ho RY; Simpson HM; Hattori SI; Hayashi H; Agniswamy J; Wang YF; Weber IT; Mitsuya H
J Med Chem; 2018 Nov; 61(21):9722-9737. PubMed ID: 30354121
[TBL] [Abstract][Full Text] [Related]
14. Design and evaluation of novel piperidine HIV-1 protease inhibitors with potency against DRV-resistant variants.
Zhu M; Zhou H; Ma L; Dong B; Zhou J; Zhang G; Wang M; Wang J; Cen S; Wang Y
Eur J Med Chem; 2021 Aug; 220():113450. PubMed ID: 33906049
[TBL] [Abstract][Full Text] [Related]
15. Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants.
Ghosh AK; Rao KV; Nyalapatla PR; Osswald HL; Martyr CD; Aoki M; Hayashi H; Agniswamy J; Wang YF; Bulut H; Das D; Weber IT; Mitsuya H
J Med Chem; 2017 May; 60(10):4267-4278. PubMed ID: 28418652
[TBL] [Abstract][Full Text] [Related]
16. Potent HIV-1 protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structure-based design, synthesis, biological evaluation and protein-ligand X-ray studies.
Ghosh AK; Gemma S; Takayama J; Baldridge A; Leshchenko-Yashchuk S; Miller HB; Wang YF; Kovalevsky AY; Koh Y; Weber IT; Mitsuya H
Org Biomol Chem; 2008 Oct; 6(20):3703-13. PubMed ID: 18843400
[TBL] [Abstract][Full Text] [Related]
17. Structure-based design of potent HIV-1 protease inhibitors with modified P1-biphenyl ligands: synthesis, biological evaluation, and enzyme-inhibitor X-ray structural studies.
Ghosh AK; Yu X; Osswald HL; Agniswamy J; Wang YF; Amano M; Weber IT; Mitsuya H
J Med Chem; 2015 Jul; 58(13):5334-43. PubMed ID: 26107245
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of HIV-1 protease inhibitors. Novel tetrahydrofuran P2/P2'-groups interacting with Asp29/30 of the HIV-1 protease. Determination of binding from X-ray crystal structure of inhibitor protease complex.
Oscarsson K; Lahmann M; Lindberg J; Kangasmetsä J; Unge T; Oscarson S; Hallberg A; Samuelsson B
Bioorg Med Chem; 2003 Mar; 11(6):1107-15. PubMed ID: 12614898
[TBL] [Abstract][Full Text] [Related]
19. Structural Analysis of Potent Hybrid HIV-1 Protease Inhibitors Containing Bis-tetrahydrofuran in a Pseudosymmetric Dipeptide Isostere.
Rusere LN; Lockbaum GJ; Henes M; Lee SK; Spielvogel E; Rao DN; Kosovrasti K; Nalivaika EA; Swanstrom R; Kurt Yilmaz N; Schiffer CA; Ali A
J Med Chem; 2020 Aug; 63(15):8296-8313. PubMed ID: 32672965
[TBL] [Abstract][Full Text] [Related]
20. Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands.
Ghosh AK; Takayama J; Kassekert LA; Ella-Menye JR; Yashchuk S; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
Bioorg Med Chem Lett; 2015 Nov; 25(21):4903-4909. PubMed ID: 26096678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
